Q-omics provides the consensus-scored TRIM43 profile across patient tissues and cancer cell-line models. TRIM43 expression is associated with patient survival in 15 of 34 cancer types, with the highest sampling consensus in BLCA. Among the 18 cancer types available for tumor–normal comparison, TRIM43 is differentially expressed in 5, with the highest sampling consensus in LUSC. Additionally, TRIM43 RNA expression shows 10,861 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight BLCA, LUSC, and THYM as cancer lineages where TRIM43 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TRIM43 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TRIM43 survival associations across molecular data types. TRIM43 RNA expression shows survival associations in the most cancer types (15), followed by mutation status (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TRIM43 RNA expression–survival associations across cancer types. High TRIM43 expression shows unfavorable associations in BLCA, UVM, MESO, KIRC, CESC and KICH. The BLCA Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify BLCA as the clearest survival context for TRIM43 RNA expression.
This table summarizes TRIM43 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 5. The strongest signals are observed in LUSC for RNA.
This table ranks reproducible tumor–normal expression differences for TRIM43. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TRIM43 shows lower tumor expression in BRCA and higher tumor expression in LUSC, UCEC, LUAD and STAD. The LUSC box plot shows higher TRIM43 RNA expression in tumor versus normal tissue (log2 FC = +0.080, t-test p = .019).
This table shows molecular features associated with TRIM43 in patient tissues and cancer cell lines. In patient samples, TRIM43 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, TRIM43 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Leukemia, while CRISPR and shRNA rows add functional-dependency signals in PANCREAS and LUNG_NSCLC_LUSC.
